Showing 161-170 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeting Prostaglandin F-series Lipids to Counter Beta-Cell-Death and T1D Development | The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham | Sasanka Ramanadham | Cures | 01-May-2023 to 30-April-2027 | $749,763.00 |
| Immune-cell targeted TLR7 antagonist to halt the attack on beta−cells in the context of Type 1 Diabetes | Tezcat Bio | Craig Ramirez | Cures | 15-January-2026 to 31-December-2026 | $100,000.00 |
| Minimally Invasive Microneedle Platform for High-Resolution C-Peptide Monitoring | Texas A&M Engineering Experiment Station (TEES) | Limei Tian | Cures | 01-November-2026 to 31-October-2029 | $895,589.13 |
| Implementing Best Practice Advisories to Reduce Inequities in Technology Use for people with Type 1 Diabetes | T1D Exchange, Inc. | Nicole Rioles | Improving Lives | 01-May-2024 to 30-April-2027 | $1,995,534.06 |
| Programming Pancreatic Cell Replacement Therapeutics Using Cellgorithm Technology | Syntax Bio, Inc | Ryan Clarke | Cures | 15-November-2025 to 14-November-2027 | $856,250.00 |
| Building the Evidence to Address Disparities in Young children with Type 1 Diabetes: BEADY-T1D | Stanford University | Ananta Addala | Improving Lives | 01-February-2025 to 31-January-2029 | $943,983.20 |
| Development of ultrarapid insulin for automated insulin dosing systems | Stanford University | Danny Hung-Chieh Chou | Improving Lives | 01-July-2026 to 30-June-2028 | $1,036,315.00 |
| Ultrafast Insulin-Pramlintide Co-formulations | Stanford University | Eric Appel | Improving Lives | 01-September-2022 to 31-December-2026 | $794,960.90 |
| Development of an injectable immunomodulatory niche technology for induction of immune tolerance to islet cell transplants | Stanford University | Eric Appel | Cures | 01-January-2025 to 31-December-2026 | $600,000.00 |
| Endothelial cells for islet replacement in diabetes | Stanford University | Martin Neukam | Cures | 01-April-2024 to 31-March-2027 | $251,600.00 |